Depletion of FTO suppressed the expression of PD-1 (PDCD1), CXCR4, and SOX10 genes through m6A/YTHDF2-mediated mRNA decay and thus sensitized melanoma cells to interferon-gamma (IFN-γ) and anti-PD-1 blockade immunotherapy; this finding suggests that the combination of FTO inhibitors with anti-PD-1 treatment might be beneficial to reduce the resistance of melanoma to immunotherapy [99]. The gene discussed is CXCR4; the disease is melanoma.